BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 9, 2016--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing CODIT™ (Characterized Oral Desensitization
ImmunoTherapy) treatments for life-threatening food
allergies, today announced that Stephen G. Dilly, M.B.B.S., Ph.D., Chief
Executive Officer of Aimmune, will present a company overview at the
2016 Wedbush PacGrow Healthcare Conference in New York City, on Tuesday,
August 16, 2016, at 9:10 a.m. Eastern Time.
The live webcast of the presentation will be accessible on the Events
page under the Investor Relations section of the Aimmune website at www.aimmune.com.
The replay of the webcast will be available for 14 days following the
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), uses
rigorously characterized product candidates with gradual, controlled
up-dosing protocols to obtain clinically meaningful desensitization to
food allergens. Aimmune’s first CODIT product, AR101 for the treatment
of peanut allergy, has received the FDA’s Breakthrough Therapy
Designation for the desensitization of peanut-allergic patients 4-17
years of age. Aimmune’s Phase 3 trial of AR101, PALISADE, is now
enrolling patients. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160809005568/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,